PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
34726809-10	2021	Osteoblasts reduced cholesterol synthesis in chondrocytes by reducing the expression of a series of synthetases, including Fdft1, Sqle, Lss, Cyp51, Msmo1, Nsdhl, Sc5d, Dhcr24 and Dhcr7.	Cholesterol	20-31	lanosterol synthase	Homo sapiens	136-139
34751594-2	2022	Minimally invasive lumbar decompression (commonly known as the mild Procedure) and epidural steroid injections are both common treatment options for lumbar spinal stenosis (commonly referred to as LSS), a condition that causes chronic lower back pain in older adults.	Steroids	92-99	lanosterol synthase	Homo sapiens	197-200
34751594-3	2022	To determine how to best treat LSS patients, healthcare professionals use a guide to help with the decision-making process (called an algorithm) to pass through non-medical to more invasive therapies that often includes one or more epidural steroid injections.	Steroids	241-248	lanosterol synthase	Homo sapiens	31-34
34440098-4	2021	This work is aimed at systematization and bioinformatic analysis of the available interactomics data on seventeen enzymes in the cholesterol pathway, encoded by HMGCR, MVK, PMVK, MVD, FDPS, FDFT1, SQLE, LSS, DHCR24, CYP51A1, TM7SF2, MSMO1, NSDHL, HSD17B7, EBP, SC5D, DHCR7 genes.	Cholesterol	129-140	lanosterol synthase	Homo sapiens	203-206
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	Cholesterol	62-73	lanosterol synthase	Homo sapiens	0-3
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	Cholesterol	62-73	lanosterol synthase	Homo sapiens	12-31
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	Cholesterol	62-73	lanosterol synthase	Homo sapiens	33-36
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	2,3-oxidosqualene	109-130	lanosterol synthase	Homo sapiens	0-3
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	2,3-oxidosqualene	109-130	lanosterol synthase	Homo sapiens	12-31
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	2,3-oxidosqualene	109-130	lanosterol synthase	Homo sapiens	33-36
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	Lanosterol	134-144	lanosterol synthase	Homo sapiens	0-3
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	Lanosterol	134-144	lanosterol synthase	Homo sapiens	12-31
35413293-4	2022	LSS encodes lanosterol synthase (LSS), which functions in the cholesterol biosynthesis pathway by converting (S)-2,3-oxidosqualene to lanosterol.	Lanosterol	134-144	lanosterol synthase	Homo sapiens	33-36
35413293-8	2022	Remarkably decreased lanosterol levels were found in vitro in three LSS variants, LSS-DeltaN80, p.Ile342Ser, and p.Gly508Trp, suggesting loss of enzymatic activity.	Lanosterol	21-31	lanosterol synthase	Homo sapiens	68-71
35413293-8	2022	Remarkably decreased lanosterol levels were found in vitro in three LSS variants, LSS-DeltaN80, p.Ile342Ser, and p.Gly508Trp, suggesting loss of enzymatic activity.	Lanosterol	21-31	lanosterol synthase	Homo sapiens	82-85
35413293-10	2022	Taken together, our findings indicate LSS as a causative gene for PPKCA2, which emphasizes the importance of cholesterol synthesis pathway in human skin cornification.	Cholesterol	109-120	lanosterol synthase	Homo sapiens	38-41
35197069-13	2022	Analysis with qRT-PCR suggested that combination treatment decreased cholesterol biosynthesis genes DHCR24 (24-dehydrocholesterol reductase) and LSS (lanosterol synthase) but increased genes involved in glycolysis and TCA cycle.	Cholesterol	69-80	lanosterol synthase	Homo sapiens	150-169
34029588-7	2021	Following this observation, a proteomic screen of the viperin interactome identified several cholesterol biosynthetic enzymes among the top hits, including lanosterol synthase (LS) and squalene monooxygenase (MS), which are enzymes that catalyze key steps in establishing the sterol carbon skeleton.	Cholesterol	93-104	lanosterol synthase	Homo sapiens	156-175
34029588-7	2021	Following this observation, a proteomic screen of the viperin interactome identified several cholesterol biosynthetic enzymes among the top hits, including lanosterol synthase (LS) and squalene monooxygenase (MS), which are enzymes that catalyze key steps in establishing the sterol carbon skeleton.	Carbon	283-289	lanosterol synthase	Homo sapiens	156-175
33636107-0	2021	Modulation of lanosterol synthase drives 24,25-epoxysterol synthesis and oligodendrocyte formation.	24,25-epoxysterol	41-58	lanosterol synthase	Homo sapiens	14-33
33636107-5	2021	Increasing flux through the epoxycholesterol shunt using genetic manipulation or small-molecule inhibition of lanosterol synthase (LSS) increased endogenous 24,25-epoxycholesterol levels and OPC differentiation.	cholesterol alpha-oxide	28-44	lanosterol synthase	Homo sapiens	110-129
33636107-5	2021	Increasing flux through the epoxycholesterol shunt using genetic manipulation or small-molecule inhibition of lanosterol synthase (LSS) increased endogenous 24,25-epoxycholesterol levels and OPC differentiation.	cholesterol alpha-oxide	28-44	lanosterol synthase	Homo sapiens	131-134
33636107-5	2021	Increasing flux through the epoxycholesterol shunt using genetic manipulation or small-molecule inhibition of lanosterol synthase (LSS) increased endogenous 24,25-epoxycholesterol levels and OPC differentiation.	24,25-epoxycholesterol	157-179	lanosterol synthase	Homo sapiens	110-129
33636107-5	2021	Increasing flux through the epoxycholesterol shunt using genetic manipulation or small-molecule inhibition of lanosterol synthase (LSS) increased endogenous 24,25-epoxycholesterol levels and OPC differentiation.	24,25-epoxycholesterol	157-179	lanosterol synthase	Homo sapiens	131-134
33636107-7	2021	This work highlights epoxycholesterol shunt usage, controlled by inhibitors of LSS, as a target to promote oligodendrocyte formation.	cholesterol alpha-oxide	21-37	lanosterol synthase	Homo sapiens	79-82
32986402-7	2020	All the anisotropic OSC molecules grown on poly(3,4-ethylenedioxythiophene)-polystyrene sulfonate (PEDOT:PSS) electrodes show a greater degree of molecular ordering than those grown on Au and multiwalled carbon nanotube/PEDOT:PSS electrodes.	poly(3,4-ethylenedioxythiophene)-poly(styrenesulfonate)	43-97	lanosterol synthase	Homo sapiens	20-23
32986402-7	2020	All the anisotropic OSC molecules grown on poly(3,4-ethylenedioxythiophene)-polystyrene sulfonate (PEDOT:PSS) electrodes show a greater degree of molecular ordering than those grown on Au and multiwalled carbon nanotube/PEDOT:PSS electrodes.	pedot	99-104	lanosterol synthase	Homo sapiens	20-23
32986402-7	2020	All the anisotropic OSC molecules grown on poly(3,4-ethylenedioxythiophene)-polystyrene sulfonate (PEDOT:PSS) electrodes show a greater degree of molecular ordering than those grown on Au and multiwalled carbon nanotube/PEDOT:PSS electrodes.	Gold	185-187	lanosterol synthase	Homo sapiens	20-23
32986402-7	2020	All the anisotropic OSC molecules grown on poly(3,4-ethylenedioxythiophene)-polystyrene sulfonate (PEDOT:PSS) electrodes show a greater degree of molecular ordering than those grown on Au and multiwalled carbon nanotube/PEDOT:PSS electrodes.	Carbon	204-210	lanosterol synthase	Homo sapiens	20-23
32877255-2	2020	Lanosterol synthase (LSS) and 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) are the limiting enzymes in the process of synthesis of lanosterol.	Lanosterol	142-152	lanosterol synthase	Homo sapiens	0-19
32629436-3	2020	In line with these findings, OSC and Col1A1 protein expression was also detected in BM-MSCs on the CS:Gel scaffolds at day 14 of osteogenic differentiation.	Cesium	99-101	lanosterol synthase	Homo sapiens	29-32
32554062-3	2020	OS carboxylate (OSC), the active form of OS, is formed by the action of endogenous esterase, which targets NA and is shown to significantly reduce influenza-related deaths.	oseltamivir carboxylate	0-14	lanosterol synthase	Homo sapiens	16-19
32235572-6	2020	Expression of FDPS and OSC, enzymes involved in cholesterol synthesis, are decreased both in drug-resistant cells and upon TRAP1 silencing, whereas the expression of LDL receptor, the main mediator of extracellular cholesterol uptake, is increased.	Cholesterol	48-59	lanosterol synthase	Homo sapiens	23-26
32101538-6	2020	We showed that the blockade of the LSS enzyme reaction occurred in the patients by measuring the (S)-2,3-epoxysqualene/lanosterol ratio in the forehead sebum, which would be a good biomarker for the diagnosis of LSS deficiency.	oxidosqualene	97-118	lanosterol synthase	Homo sapiens	35-38
32101538-6	2020	We showed that the blockade of the LSS enzyme reaction occurred in the patients by measuring the (S)-2,3-epoxysqualene/lanosterol ratio in the forehead sebum, which would be a good biomarker for the diagnosis of LSS deficiency.	oxidosqualene	97-118	lanosterol synthase	Homo sapiens	212-215
32101538-6	2020	We showed that the blockade of the LSS enzyme reaction occurred in the patients by measuring the (S)-2,3-epoxysqualene/lanosterol ratio in the forehead sebum, which would be a good biomarker for the diagnosis of LSS deficiency.	Lanosterol	119-129	lanosterol synthase	Homo sapiens	35-38
32101538-6	2020	We showed that the blockade of the LSS enzyme reaction occurred in the patients by measuring the (S)-2,3-epoxysqualene/lanosterol ratio in the forehead sebum, which would be a good biomarker for the diagnosis of LSS deficiency.	Lanosterol	119-129	lanosterol synthase	Homo sapiens	212-215
31760884-6	2020	Regression analysis of BP values with genetic polymorphisms, highlighted an association with a missense variant of LSS (lanosterol synthase, rs2254524), a gene coding for an enzyme involved in endogenous ouabain synthesis.	Ouabain	204-211	lanosterol synthase	Homo sapiens	120-139
30723320-0	2019	Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome.	Cholesterol	82-93	lanosterol synthase	Homo sapiens	37-56
30723320-0	2019	Biallelic pathogenic variants in the lanosterol synthase gene LSS involved in the cholesterol biosynthesis cause alopecia with intellectual disability, a rare recessive neuroectodermal syndrome.	Cholesterol	82-93	lanosterol synthase	Homo sapiens	62-65
30723320-11	2019	CONCLUSION: In the cholesterol biosynthesis pathway, lanosterol synthase leads to the cyclization of (S)-2,3-oxidosqualene into lanosterol.	Cholesterol	19-30	lanosterol synthase	Homo sapiens	53-72
30723320-11	2019	CONCLUSION: In the cholesterol biosynthesis pathway, lanosterol synthase leads to the cyclization of (S)-2,3-oxidosqualene into lanosterol.	2,3-oxidosqualene	101-122	lanosterol synthase	Homo sapiens	53-72
30660405-2	2019	We sought to examine the relationship among EO levels, genetic variants in lanosterol synthase (LSS; an enzyme that catalyzes synthesis of cholesterol, a precursor of EO), and both AKI and chronic kidney injury.	Cholesterol	139-150	lanosterol synthase	Homo sapiens	75-94
30660405-2	2019	We sought to examine the relationship among EO levels, genetic variants in lanosterol synthase (LSS; an enzyme that catalyzes synthesis of cholesterol, a precursor of EO), and both AKI and chronic kidney injury.	Cholesterol	139-150	lanosterol synthase	Homo sapiens	96-99
30660405-11	2019	LIMITATIONS: These associations do not necessarily represent causal relationships; LSS rs2254524 variants may have effects on other steroid hormones.	Steroids	132-139	lanosterol synthase	Homo sapiens	83-86
30740816-4	2019	The ability of Os and Os-C to induce reactive oxygen species (ROS) and to protect against 2,2"-azobis(2-amidinopropane) dihydrochloride-induced oxidative damage in both cell populations was evaluated using 2",7"-dichlorofluorescin diacetate (DCFH-DA).	Reactive Oxygen Species	37-60	lanosterol synthase	Homo sapiens	22-26
30740816-4	2019	The ability of Os and Os-C to induce reactive oxygen species (ROS) and to protect against 2,2"-azobis(2-amidinopropane) dihydrochloride-induced oxidative damage in both cell populations was evaluated using 2",7"-dichlorofluorescin diacetate (DCFH-DA).	Reactive Oxygen Species	62-65	lanosterol synthase	Homo sapiens	22-26
30740816-4	2019	The ability of Os and Os-C to induce reactive oxygen species (ROS) and to protect against 2,2"-azobis(2-amidinopropane) dihydrochloride-induced oxidative damage in both cell populations was evaluated using 2",7"-dichlorofluorescin diacetate (DCFH-DA).	2,2'-azobis(2-amidinopropane)	90-135	lanosterol synthase	Homo sapiens	22-26
30740816-8	2019	Os-C caused MN and PMN leukocyte activation associated with ROS formation and was unable to penetrate cell membranes, indicating extracellular membrane interactions.	Reactive Oxygen Species	60-63	lanosterol synthase	Homo sapiens	0-4
30740816-11	2019	In contrast, the ability of Os-C to activate MN and PMN cells implies that this peptide should be further evaluated as an AMP, which, in addition to its ability to eradicate infection, can further enhance host immunity.	Adenosine Monophosphate	122-125	lanosterol synthase	Homo sapiens	28-32
30740816-12	2019	These novel characteristics of Os and Os-C indicate that these AMPs as peptides can be further developed for specific applications.	Adenylyl sulfate	63-67	lanosterol synthase	Homo sapiens	38-42
30084659-3	2018	Through RNA interference library screening, we identified lanosterol synthase (LSS), a component of the cholesterol biosynthetic pathway, as a novel regulator of RV replication in primary normal human bronchial epithelial cells.	Cholesterol	104-115	lanosterol synthase	Homo sapiens	58-77
30084659-3	2018	Through RNA interference library screening, we identified lanosterol synthase (LSS), a component of the cholesterol biosynthetic pathway, as a novel regulator of RV replication in primary normal human bronchial epithelial cells.	Cholesterol	104-115	lanosterol synthase	Homo sapiens	79-82
30084659-8	2018	We showed that LSS inhibition led to an induction of 24(S),25 epoxycholesterol, an important regulator of the sterol pathway.	cholesterol alpha-oxide	62-78	lanosterol synthase	Homo sapiens	15-18
30084659-8	2018	We showed that LSS inhibition led to an induction of 24(S),25 epoxycholesterol, an important regulator of the sterol pathway.	Sterols	72-78	lanosterol synthase	Homo sapiens	15-18
30084659-10	2018	We found LSS to be a novel regulator of RV replication and innate antiviral immunity and identified a potential molecular mechanism for this effect, via induction of 24(S),25 epoxycholesterol.	cholesterol alpha-oxide	175-191	lanosterol synthase	Homo sapiens	9-12
30401459-5	2018	LSS encodes lanosterol synthase (LSS), which is a key enzyme in the cholesterol biosynthetic pathway.	Cholesterol	68-79	lanosterol synthase	Homo sapiens	0-3
30401459-5	2018	LSS encodes lanosterol synthase (LSS), which is a key enzyme in the cholesterol biosynthetic pathway.	Cholesterol	68-79	lanosterol synthase	Homo sapiens	12-31
30401459-5	2018	LSS encodes lanosterol synthase (LSS), which is a key enzyme in the cholesterol biosynthetic pathway.	Cholesterol	68-79	lanosterol synthase	Homo sapiens	33-36
30401459-12	2018	The identification of LSS as causal gene for autosomal-recessive HS highlights the importance of the cholesterol pathway in hair follicle biology and may facilitate novel therapeutic approaches for hair loss disorders in general.	Cholesterol	101-112	lanosterol synthase	Homo sapiens	22-25
30116630-6	2018	Results: In lens epithelial cells (LECs), LSS expression in LECs increased with opaque degree C II, while it decreased with opaque degree C IV and C V. While in the cortex of age-related cortical cataract (ARCC), LSS expression was negatively related to opaque degree, while lanosterol level was positively correlated to opaque degree.	Lanosterol	275-285	lanosterol synthase	Homo sapiens	42-45
28462697-1	2017	BACKGROUND: Lanosterol synthase (Oxidosqualene cyclase) is an enzyme, which plays a central role in cholesterol and sterols biosynthesis.	Cholesterol	100-111	lanosterol synthase	Homo sapiens	12-31
28462697-1	2017	BACKGROUND: Lanosterol synthase (Oxidosqualene cyclase) is an enzyme, which plays a central role in cholesterol and sterols biosynthesis.	Sterols	116-123	lanosterol synthase	Homo sapiens	12-31
28462697-2	2017	Lanosterol synthase drugs are used to lower the level of cholesterol in the blood and treat wide variety of diseases like atherosclerosis, coronary heart diseases etc.	Cholesterol	57-68	lanosterol synthase	Homo sapiens	0-19
26667413-0	2016	Lanosterol Synthase Gene Polymorphisms and Changes in Endogenous Ouabain in the Response to Low Sodium Intake.	Sodium	96-102	lanosterol synthase	Homo sapiens	0-19
26667413-2	2016	Furthermore, lanosterol synthase, an enzyme involved in cholesterol biosynthesis, has a missense polymorphism (rs2254524 V642L) that affects EO biosynthesis in adrenocortical cells.	Cholesterol	56-67	lanosterol synthase	Homo sapiens	13-32
26667413-6	2016	Lanosterol synthase gene polymorphisms influence both the salt sensitivity of BP and changes in circulating EO in response to a low salt diet.	Salts	58-62	lanosterol synthase	Homo sapiens	0-19
26667413-6	2016	Lanosterol synthase gene polymorphisms influence both the salt sensitivity of BP and changes in circulating EO in response to a low salt diet.	Salts	132-136	lanosterol synthase	Homo sapiens	0-19
26698156-5	2016	Treatment of CEM and CEM/R2 cells with cholesterol biosynthesis inhibitors acting on the enzymes squalene epoxidase and lanosterol synthase, both also involved in the 24,25-epoxycholesterol shunt pathway, revealed a connection of this pathway to lanosterol turnover.	Cholesterol	39-50	lanosterol synthase	Homo sapiens	120-139
26698156-5	2016	Treatment of CEM and CEM/R2 cells with cholesterol biosynthesis inhibitors acting on the enzymes squalene epoxidase and lanosterol synthase, both also involved in the 24,25-epoxycholesterol shunt pathway, revealed a connection of this pathway to lanosterol turnover.	24,25-epoxycholesterol	167-189	lanosterol synthase	Homo sapiens	120-139
25855471-1	2015	PURPOSE: 2,3-Oxidosqualene cyclase (OSC), an important enzyme of cholesterol biosynthesis, catalyzes the highly selective cyclization of 2,3-monoepoxysqualene to lanosterol.	Cholesterol	65-76	lanosterol synthase	Homo sapiens	9-34
25855471-1	2015	PURPOSE: 2,3-Oxidosqualene cyclase (OSC), an important enzyme of cholesterol biosynthesis, catalyzes the highly selective cyclization of 2,3-monoepoxysqualene to lanosterol.	Cholesterol	65-76	lanosterol synthase	Homo sapiens	36-39
25855471-1	2015	PURPOSE: 2,3-Oxidosqualene cyclase (OSC), an important enzyme of cholesterol biosynthesis, catalyzes the highly selective cyclization of 2,3-monoepoxysqualene to lanosterol.	2,3-monoepoxysqualene	137-158	lanosterol synthase	Homo sapiens	9-34
25855471-1	2015	PURPOSE: 2,3-Oxidosqualene cyclase (OSC), an important enzyme of cholesterol biosynthesis, catalyzes the highly selective cyclization of 2,3-monoepoxysqualene to lanosterol.	2,3-monoepoxysqualene	137-158	lanosterol synthase	Homo sapiens	36-39
25855471-1	2015	PURPOSE: 2,3-Oxidosqualene cyclase (OSC), an important enzyme of cholesterol biosynthesis, catalyzes the highly selective cyclization of 2,3-monoepoxysqualene to lanosterol.	Lanosterol	162-172	lanosterol synthase	Homo sapiens	9-34
25855471-1	2015	PURPOSE: 2,3-Oxidosqualene cyclase (OSC), an important enzyme of cholesterol biosynthesis, catalyzes the highly selective cyclization of 2,3-monoepoxysqualene to lanosterol.	Lanosterol	162-172	lanosterol synthase	Homo sapiens	36-39
25855471-11	2015	Moreover, over-expression of OSC could attenuate IH-induced cellular triglyceride accumulation.	Ile-His	49-51	lanosterol synthase	Homo sapiens	29-32
25855471-11	2015	Moreover, over-expression of OSC could attenuate IH-induced cellular triglyceride accumulation.	Triglycerides	69-81	lanosterol synthase	Homo sapiens	29-32
25855471-12	2015	CONCLUSIONS: These findings suggest that OSC are involved in IH-induced hepatic cell injury.	Ile-His	61-63	lanosterol synthase	Homo sapiens	41-44
25962741-2	2015	Human oxidosqualene cyclase (hOSC) is a membrane-bound triterpene cyclase that catalyzes the formation of the tetracyclic steroidal backbone, a key step in cholesterol biosynthesis.	Cholesterol	156-167	lanosterol synthase	Homo sapiens	29-33
26200341-6	2015	It is synthesized by lanosterol synthase (LSS) in a key cyclization reaction of a cholesterol synthesis pathway.	Cholesterol	82-93	lanosterol synthase	Homo sapiens	21-40
26200341-6	2015	It is synthesized by lanosterol synthase (LSS) in a key cyclization reaction of a cholesterol synthesis pathway.	Cholesterol	82-93	lanosterol synthase	Homo sapiens	42-45
23583910-1	2013	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann"s ketone.	aminopropylindenes	12-30	lanosterol synthase	Homo sapiens	97-121
23583910-1	2013	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann"s ketone.	aminopropylindenes	12-30	lanosterol synthase	Homo sapiens	123-126
23583910-1	2013	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann"s ketone.	2,3-oxidosqualen	152-168	lanosterol synthase	Homo sapiens	97-121
23583910-1	2013	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann"s ketone.	2,3-oxidosqualen	152-168	lanosterol synthase	Homo sapiens	123-126
23583910-1	2013	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann"s ketone.	Lanosterol	172-182	lanosterol synthase	Homo sapiens	97-121
23583910-1	2013	A series of aminopropylindenes, designed as mimics of a cationic high energy intermediate in the oxidosqualene cyclase(1) (OSC)-mediated cyclization of 2,3-oxidosqualen to lanosterol was prepared from Grundmann"s ketone.	Grundmann's ketone	201-219	lanosterol synthase	Homo sapiens	97-121
23130825-1	2012	Oxidosqualene-lanosterol cyclase (OSC) is a key enzyme in the biosynthesis of cholesterol.	Cholesterol	78-89	lanosterol synthase	Homo sapiens	0-32
23130825-1	2012	Oxidosqualene-lanosterol cyclase (OSC) is a key enzyme in the biosynthesis of cholesterol.	Cholesterol	78-89	lanosterol synthase	Homo sapiens	34-37
23130825-5	2012	We show that the product specificity of OSC at the hydride/methyl-shifting stage is unlikely to be achieved by the stabilization of the cationic intermediates, as the precursor of lanosterol is in fact not the most stable cationic intermediate for wild-type OSC.	Lanosterol	180-190	lanosterol synthase	Homo sapiens	40-43
22933236-1	2012	Lanosterol synthase catalyzes the polycyclization reaction of (3S)-2,3-oxidosqualene (1) into tetracyclic lanosterol 2 by folding 1 in a chair-boat-chair-chair conformation.	(S)-2,3-Epoxysqualene	62-84	lanosterol synthase	Homo sapiens	0-19
22933236-1	2012	Lanosterol synthase catalyzes the polycyclization reaction of (3S)-2,3-oxidosqualene (1) into tetracyclic lanosterol 2 by folding 1 in a chair-boat-chair-chair conformation.	Lanosterol	106-116	lanosterol synthase	Homo sapiens	0-19
22137785-2	2012	All of these inhibitors were revealed to have activities comparable or superior to that of LDAO, a known OSC inhibitor.	dodecyldimethylamine oxide	91-95	lanosterol synthase	Homo sapiens	105-108
19522517-5	2009	Each ruthenium (osmium) atom is covalently bonded to four C(2) pairs with Ru-C (Os-C) distances of 220-222 pm.	Ruthenium	5-14	lanosterol synthase	Homo sapiens	80-84
19522517-5	2009	Each ruthenium (osmium) atom is covalently bonded to four C(2) pairs with Ru-C (Os-C) distances of 220-222 pm.	Osmium	16-22	lanosterol synthase	Homo sapiens	80-84
18480904-4	2008	The experimental results allow for an instructive comparison with the enzymic processes, particularly those of the cyclases in steroid biosynthesis (i.e. lanosterol synthase).	Steroids	127-134	lanosterol synthase	Homo sapiens	154-173
18324586-6	2008	Solely the treatment of LSS with epidural steroids, which is recommended by most of the authors, has been evaluated by several randomised controlled studies with a high level of evidence.	Steroids	42-50	lanosterol synthase	Homo sapiens	24-27
17925399-0	2007	Histone deacetylase 3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression.	Cholesterol	37-48	lanosterol synthase	Homo sapiens	81-100
17925399-3	2007	Because of the crucial role that lanosterol synthase plays in cholesterol biosynthesis, there is great interest in the identification of drugs that target this enzyme for anticholesteremic purposes.	Cholesterol	62-73	lanosterol synthase	Homo sapiens	33-52
17444640-3	2007	These are mono- and bis-Pt(PBut3) adducts of 9 formed by the addition of a Pt(PBut3) group to the Os-Os bond in 11 and the Os-Os bond and Os-C bond to the sigma-bonded phenyl group in 12.	Platinum	23-26	lanosterol synthase	Homo sapiens	138-142
17444640-3	2007	These are mono- and bis-Pt(PBut3) adducts of 9 formed by the addition of a Pt(PBut3) group to the Os-Os bond in 11 and the Os-Os bond and Os-C bond to the sigma-bonded phenyl group in 12.	Osmium	98-100	lanosterol synthase	Homo sapiens	138-142
17444640-3	2007	These are mono- and bis-Pt(PBut3) adducts of 9 formed by the addition of a Pt(PBut3) group to the Os-Os bond in 11 and the Os-Os bond and Os-C bond to the sigma-bonded phenyl group in 12.	Osmium	101-103	lanosterol synthase	Homo sapiens	138-142
17444640-3	2007	These are mono- and bis-Pt(PBut3) adducts of 9 formed by the addition of a Pt(PBut3) group to the Os-Os bond in 11 and the Os-Os bond and Os-C bond to the sigma-bonded phenyl group in 12.	Osmium	101-103	lanosterol synthase	Homo sapiens	138-142
17444640-3	2007	These are mono- and bis-Pt(PBut3) adducts of 9 formed by the addition of a Pt(PBut3) group to the Os-Os bond in 11 and the Os-Os bond and Os-C bond to the sigma-bonded phenyl group in 12.	Osmium	101-103	lanosterol synthase	Homo sapiens	138-142
17145976-11	2007	Wethers fed the Osc diet tended (P = 0.06) to have a greater PDV uptake of urea N than did those fed the Medium diet, but there was no difference between the Osc and Medium diets (P = 0.72) in hepatic urea N release.	urea n	75-81	lanosterol synthase	Homo sapiens	16-19
16435854-0	2006	A putative precursor of isomalabaricane triterpenoids from lanosterol synthase mutants.	isomalabaricane	24-39	lanosterol synthase	Homo sapiens	59-78
16435854-0	2006	A putative precursor of isomalabaricane triterpenoids from lanosterol synthase mutants.	triterpenoids	40-53	lanosterol synthase	Homo sapiens	59-78
16435854-2	2006	Known lanosterol synthase mutants produce monocyclic or tetracyclic byproducts from oxidosqualene.	oxidosqualene	84-97	lanosterol synthase	Homo sapiens	6-25
16320765-0	2005	Revised structures of epohelmins A and B isolated as lanosterol synthase inhibitors from a fungal strain FKI-0929.	fki-0929	105-113	lanosterol synthase	Homo sapiens	53-72
15951028-2	2005	OSC catalyzes the cyclization of the linear 2,3-monoepoxysqualene to lanosterol, the initial four-ringed sterol intermediate in the cholesterol biosynthetic pathway.	2,3-monoepoxysqualene	44-65	lanosterol synthase	Homo sapiens	0-3
15951028-2	2005	OSC catalyzes the cyclization of the linear 2,3-monoepoxysqualene to lanosterol, the initial four-ringed sterol intermediate in the cholesterol biosynthetic pathway.	Lanosterol	69-79	lanosterol synthase	Homo sapiens	0-3
15951028-2	2005	OSC catalyzes the cyclization of the linear 2,3-monoepoxysqualene to lanosterol, the initial four-ringed sterol intermediate in the cholesterol biosynthetic pathway.	Sterols	73-79	lanosterol synthase	Homo sapiens	0-3
15951028-2	2005	OSC catalyzes the cyclization of the linear 2,3-monoepoxysqualene to lanosterol, the initial four-ringed sterol intermediate in the cholesterol biosynthetic pathway.	Cholesterol	132-143	lanosterol synthase	Homo sapiens	0-3
15951028-3	2005	OSC also catalyzes the formation of 24(S),25-epoxycholesterol, a ligand activator of the liver X receptor.	24,25-epoxycholesterol	36-61	lanosterol synthase	Homo sapiens	0-3
15951028-4	2005	Inhibition of OSC reduces cholesterol biosynthesis and selectively enhances 24(S),25-epoxycholesterol synthesis.	Cholesterol	26-37	lanosterol synthase	Homo sapiens	14-17
15951028-4	2005	Inhibition of OSC reduces cholesterol biosynthesis and selectively enhances 24(S),25-epoxycholesterol synthesis.	-epoxycholesterol	84-101	lanosterol synthase	Homo sapiens	14-17
15951028-5	2005	Through this dual mechanism, OSC inhibition decreases plasma levels of low-density lipoprotein (LDL)-cholesterol and prevents cholesterol deposition within macrophages.	Cholesterol	101-112	lanosterol synthase	Homo sapiens	29-32
15951028-5	2005	Through this dual mechanism, OSC inhibition decreases plasma levels of low-density lipoprotein (LDL)-cholesterol and prevents cholesterol deposition within macrophages.	Cholesterol	126-137	lanosterol synthase	Homo sapiens	29-32
15951028-6	2005	The recent crystallization of OSC identifies the mechanism of action for this complex enzyme, setting the stage for the design of OSC inhibitors with improved pharmacological properties for cholesterol lowering and treatment of atherosclerosis.	Cholesterol	190-201	lanosterol synthase	Homo sapiens	30-33
15951028-6	2005	The recent crystallization of OSC identifies the mechanism of action for this complex enzyme, setting the stage for the design of OSC inhibitors with improved pharmacological properties for cholesterol lowering and treatment of atherosclerosis.	Cholesterol	190-201	lanosterol synthase	Homo sapiens	130-133
16833861-0	2005	Infrared spectra and structures of the OSc(N2), OScNN, and OScNN+ complexes in solid argon.	Argon	85-90	lanosterol synthase	Homo sapiens	39-45
16833861-1	2005	Scandium monoxide-dinitrogen complexes-OSc(N2), OScNN, and OScNN+-have been prepared by the reactions of laser-evaporated scandium monoxide with N2 or scandium atoms with N2O in solid argon.	scandium monoxide	0-17	lanosterol synthase	Homo sapiens	39-45
16833861-1	2005	Scandium monoxide-dinitrogen complexes-OSc(N2), OScNN, and OScNN+-have been prepared by the reactions of laser-evaporated scandium monoxide with N2 or scandium atoms with N2O in solid argon.	Nitrogen	18-28	lanosterol synthase	Homo sapiens	39-45
16833861-1	2005	Scandium monoxide-dinitrogen complexes-OSc(N2), OScNN, and OScNN+-have been prepared by the reactions of laser-evaporated scandium monoxide with N2 or scandium atoms with N2O in solid argon.	Nitrous Oxide	171-174	lanosterol synthase	Homo sapiens	39-45
16833861-2	2005	The ground-state scandium monoxide molecule reacted with N2 to form the side-bonded OSc(N2) complex spontaneously on annealing.	scandium monoxide	17-34	lanosterol synthase	Homo sapiens	84-90
16833861-2	2005	The ground-state scandium monoxide molecule reacted with N2 to form the side-bonded OSc(N2) complex spontaneously on annealing.	Nitrogen	57-59	lanosterol synthase	Homo sapiens	84-90
16833861-4	2005	Both the OSc(N2) and OScNN complexes in solid argon can be assigned to have 2A" " electronic ground state with Cs symmetry arising from the 2Delta first excited-state ScO.	Argon	46-51	lanosterol synthase	Homo sapiens	9-15
16833861-4	2005	Both the OSc(N2) and OScNN complexes in solid argon can be assigned to have 2A" " electronic ground state with Cs symmetry arising from the 2Delta first excited-state ScO.	Cesium	111-113	lanosterol synthase	Homo sapiens	9-15
15684488-1	2005	Ethanol extracts of lyophilized vegetables were tested for inhibition of human lanosterol synthase (hOSC) in order to find the compounds to suppress cholesterol biosynthesis.	Ethanol	0-7	lanosterol synthase	Homo sapiens	100-104
15582431-0	2005	Synthesis of digalactosyl diacylglycerols and their structure-inhibitory activity on human lanosterol synthase.	digalactosyldiacylglycerol	13-41	lanosterol synthase	Homo sapiens	91-110
15582431-2	2005	The inhibitory activity of DGDG, MGDG and related compounds on human lanosterol synthase was evaluated as anti-hyperlipemic activity.	dgdg	27-31	lanosterol synthase	Homo sapiens	69-88
15582431-2	2005	The inhibitory activity of DGDG, MGDG and related compounds on human lanosterol synthase was evaluated as anti-hyperlipemic activity.	mgdg	33-37	lanosterol synthase	Homo sapiens	69-88
15525992-0	2004	Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase.	Steroids	13-20	lanosterol synthase	Homo sapiens	68-89
15525992-1	2004	In higher organisms the formation of the steroid scaffold is catalysed exclusively by the membrane-bound oxidosqualene cyclase (OSC; lanosterol synthase).	Steroids	41-48	lanosterol synthase	Homo sapiens	105-126
15525992-1	2004	In higher organisms the formation of the steroid scaffold is catalysed exclusively by the membrane-bound oxidosqualene cyclase (OSC; lanosterol synthase).	Steroids	41-48	lanosterol synthase	Homo sapiens	128-131
15525992-2	2004	In a highly selective cyclization reaction OSC forms lanosterol with seven chiral centres starting from the linear substrate 2,3-oxidosqualene.	Lanosterol	53-63	lanosterol synthase	Homo sapiens	43-46
15525992-2	2004	In a highly selective cyclization reaction OSC forms lanosterol with seven chiral centres starting from the linear substrate 2,3-oxidosqualene.	2,3-oxidosqualene	125-142	lanosterol synthase	Homo sapiens	43-46
15525992-5	2004	Because of the decisive role of OSC in cholesterol biosynthesis it represents a target for the discovery of novel anticholesteraemic drugs that could complement the widely used statins.	Cholesterol	39-50	lanosterol synthase	Homo sapiens	32-35
15525992-6	2004	Here we present two crystal structures of the human membrane protein OSC: the target protein with an inhibitor that showed cholesterol lowering in vivo opens the way for the structure-based design of new OSC inhibitors.	Cholesterol	123-134	lanosterol synthase	Homo sapiens	69-72
15525992-6	2004	Here we present two crystal structures of the human membrane protein OSC: the target protein with an inhibitor that showed cholesterol lowering in vivo opens the way for the structure-based design of new OSC inhibitors.	Cholesterol	123-134	lanosterol synthase	Homo sapiens	204-207
15580956-0	2004	Epohelmins A and B, novel lanosterol synthase inhibitors from a fungal strain FKI-0929.	fki-0929	78-86	lanosterol synthase	Homo sapiens	26-45
15580956-1	2004	From a fungal strain FKI-0929, two compounds designated epohelmins A and B, were isolated as new natural products with inhibitory activity against recombinant human lanosterol synthase.	fki-0929	21-29	lanosterol synthase	Homo sapiens	165-184
14766201-1	2004	The monotopic integral membrane protein 2,3-oxidosqualene cyclase (OSC) catalyzes the formation of lanosterol the first sterol precursor of cholesterol in mammals.	Lanosterol	99-109	lanosterol synthase	Homo sapiens	67-70
14766201-1	2004	The monotopic integral membrane protein 2,3-oxidosqualene cyclase (OSC) catalyzes the formation of lanosterol the first sterol precursor of cholesterol in mammals.	Sterols	103-109	lanosterol synthase	Homo sapiens	67-70
14766201-1	2004	The monotopic integral membrane protein 2,3-oxidosqualene cyclase (OSC) catalyzes the formation of lanosterol the first sterol precursor of cholesterol in mammals.	Cholesterol	140-151	lanosterol synthase	Homo sapiens	67-70
14766201-4	2004	The obtained IC(50) for the reference inhibitor Ro 48-8071 is nearly identical for the recombinant hOSC compared to OSC from human liver microsomes.	Ro 48-8071	48-58	lanosterol synthase	Homo sapiens	99-103
14766201-4	2004	The obtained IC(50) for the reference inhibitor Ro 48-8071 is nearly identical for the recombinant hOSC compared to OSC from human liver microsomes.	Ro 48-8071	48-58	lanosterol synthase	Homo sapiens	100-103
14512442-0	2003	Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.	Oxysterols	26-35	lanosterol synthase	Homo sapiens	94-130
14512442-0	2003	Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation.	25-epoxycholesterol	42-61	lanosterol synthase	Homo sapiens	94-130
14512442-5	2003	Macrophage synthesis of 24(S),25-epoxycholesterol, a potent LXR ligand, increased 60-fold by partial inhibition of 2,3-oxidosqualene:lanosterol cyclase (OSC), a microsomal enzyme in both the cholesterol biosynthetic pathway and the alternative oxysterol synthetic pathway.	25-epoxycholesterol	30-49	lanosterol synthase	Homo sapiens	115-151
14512442-5	2003	Macrophage synthesis of 24(S),25-epoxycholesterol, a potent LXR ligand, increased 60-fold by partial inhibition of 2,3-oxidosqualene:lanosterol cyclase (OSC), a microsomal enzyme in both the cholesterol biosynthetic pathway and the alternative oxysterol synthetic pathway.	25-epoxycholesterol	30-49	lanosterol synthase	Homo sapiens	153-156
14512442-5	2003	Macrophage synthesis of 24(S),25-epoxycholesterol, a potent LXR ligand, increased 60-fold by partial inhibition of 2,3-oxidosqualene:lanosterol cyclase (OSC), a microsomal enzyme in both the cholesterol biosynthetic pathway and the alternative oxysterol synthetic pathway.	Cholesterol	38-49	lanosterol synthase	Homo sapiens	115-151
14512442-5	2003	Macrophage synthesis of 24(S),25-epoxycholesterol, a potent LXR ligand, increased 60-fold by partial inhibition of 2,3-oxidosqualene:lanosterol cyclase (OSC), a microsomal enzyme in both the cholesterol biosynthetic pathway and the alternative oxysterol synthetic pathway.	Cholesterol	38-49	lanosterol synthase	Homo sapiens	153-156
14512442-5	2003	Macrophage synthesis of 24(S),25-epoxycholesterol, a potent LXR ligand, increased 60-fold by partial inhibition of 2,3-oxidosqualene:lanosterol cyclase (OSC), a microsomal enzyme in both the cholesterol biosynthetic pathway and the alternative oxysterol synthetic pathway.	Oxysterols	244-253	lanosterol synthase	Homo sapiens	115-151
14512442-5	2003	Macrophage synthesis of 24(S),25-epoxycholesterol, a potent LXR ligand, increased 60-fold by partial inhibition of 2,3-oxidosqualene:lanosterol cyclase (OSC), a microsomal enzyme in both the cholesterol biosynthetic pathway and the alternative oxysterol synthetic pathway.	Oxysterols	244-253	lanosterol synthase	Homo sapiens	153-156
14512442-11	2003	Furthermore, OSC inhibition significantly upregulated ABCA1 and ABCG1 expression, which led to enhanced macrophage cholesterol efflux, an effect mediated through LXR activation.	Cholesterol	115-126	lanosterol synthase	Homo sapiens	13-16
12852766-1	2003	New orally active non-terpenoic inhibitors of human 2,3-oxidosqualene cyclase (hOSC) are reported.	terpenoic	22-31	lanosterol synthase	Homo sapiens	79-83
10783007-2	2000	5.4.99.-), an enzyme of bacterial membranes catalyzing the formation of pentacyclic sterol-like triterpenes, was studied by using different classes of compounds originally developed as inhibitors of oxidosqualene cyclase (OSC) (E.C.	Triterpenes	96-107	lanosterol synthase	Homo sapiens	199-220
10783007-4	2000	The mechanism of cyclization of squalene by SHC, beginning with a protonation of the 2,3 double bond by an acidic residue of the enzyme, followed by a series of electrophilic additions of the carbocationic intermediates to the double bonds, is similar to the mechanism of cyclization of 2,3-oxidosqualene by OSC.	Squalene	32-40	lanosterol synthase	Homo sapiens	308-311
10598817-5	1999	We considered LS an excellent candidate HPE gene because of the requirement for cholesterol modification of the Sonic Hedgehog protein for the correct patterning activity of this HPE-associated protein.	Cholesterol	80-91	lanosterol synthase	Homo sapiens	14-16
9795371-17	1998	Furthermore, biochemical markers indicating bone loss (ICTP) and increased bone turnover (PTH, OSC) correlated positively with IGFBP-1 and IGFBP-4 but negatively with IGF-I, IGFBP-3 and IGFBP-5, while the opposite was observed with bone formation markers (PICP, B-ALP) and vitamin D3 metabolites.	Cholecalciferol	273-283	lanosterol synthase	Homo sapiens	95-98
9162756-0	1997	Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin.	ro 48-8.071	0-11	lanosterol synthase	Homo sapiens	19-55
9162756-3	1997	Partial inhibition of OSC should reduce synthesis of lanosterol and subsequent sterols, and also stimulate the production of epoxysterols that repress HMG-CoA reductase expression, generating a synergistic, self-limited negative regulatory loop.	Lanosterol	53-63	lanosterol synthase	Homo sapiens	22-25
9162756-11	1997	Altogether these findings clearly differentiate the OSC inhibitor Ro 48-8.071 from simvastatin, and support the view that OSC is a distinct key component in the regulation of the cholesterol synthesis pathway.	ro 48-8.071	66-77	lanosterol synthase	Homo sapiens	52-55
9162756-11	1997	Altogether these findings clearly differentiate the OSC inhibitor Ro 48-8.071 from simvastatin, and support the view that OSC is a distinct key component in the regulation of the cholesterol synthesis pathway.	Cholesterol	179-190	lanosterol synthase	Homo sapiens	52-55
9162756-11	1997	Altogether these findings clearly differentiate the OSC inhibitor Ro 48-8.071 from simvastatin, and support the view that OSC is a distinct key component in the regulation of the cholesterol synthesis pathway.	Cholesterol	179-190	lanosterol synthase	Homo sapiens	122-125
8691425-5	1996	The resulting structure-activity relationships seem to validate the mechanism of action of these inhibitors as analogs of a pro-C-8 high-energy intermediate and delineate the minimal requirements for the design of efficient isoquinoline-based, or simplified, OSC inhibitors.	isoquinoline	224-236	lanosterol synthase	Homo sapiens	259-262
7639730-1	1995	Lanosterol synthase [(S)-2,3-epoxysqualene mutase (cyclizing, lanosterol forming), EC 5.4.99.7] catalyzes the cyclization of (S)-2,3-oxidosqualene to lanosterol in the reaction that forms the sterol nucleus.	Lanosterol	62-72	lanosterol synthase	Homo sapiens	0-19
7639730-1	1995	Lanosterol synthase [(S)-2,3-epoxysqualene mutase (cyclizing, lanosterol forming), EC 5.4.99.7] catalyzes the cyclization of (S)-2,3-oxidosqualene to lanosterol in the reaction that forms the sterol nucleus.	2,3-oxidosqualene	125-146	lanosterol synthase	Homo sapiens	0-19
7639730-1	1995	Lanosterol synthase [(S)-2,3-epoxysqualene mutase (cyclizing, lanosterol forming), EC 5.4.99.7] catalyzes the cyclization of (S)-2,3-oxidosqualene to lanosterol in the reaction that forms the sterol nucleus.	Lanosterol	150-160	lanosterol synthase	Homo sapiens	0-19
1445330-0	1992	Preferential cyclization of 2,3(S):22(S),23-dioxidosqualene by mammalian 2,3-oxidosqualene-lanosterol cyclase.	-dioxidosqualene	43-59	lanosterol synthase	Homo sapiens	77-109
1445330-1	1992	Kinetic studies on the cyclization of 2,3(S)-oxido and 2,3(S):22(S),23-dioxido[14C]squalene catalyzed by liver oxidosqualene-lanosterol cyclase revealed a specificity (in terms of V/Km) of the enzyme for the diepoxide.	2,3(s)-oxido	38-50	lanosterol synthase	Homo sapiens	111-143
1445330-1	1992	Kinetic studies on the cyclization of 2,3(S)-oxido and 2,3(S):22(S),23-dioxido[14C]squalene catalyzed by liver oxidosqualene-lanosterol cyclase revealed a specificity (in terms of V/Km) of the enzyme for the diepoxide.	dioxido[14c]squalene	71-91	lanosterol synthase	Homo sapiens	111-143
1445330-1	1992	Kinetic studies on the cyclization of 2,3(S)-oxido and 2,3(S):22(S),23-dioxido[14C]squalene catalyzed by liver oxidosqualene-lanosterol cyclase revealed a specificity (in terms of V/Km) of the enzyme for the diepoxide.	diepoxide	208-217	lanosterol synthase	Homo sapiens	111-143